• Amie J Goodin, Joshua D Brown, Chris Delcher, Patricia R Freeman, Jeffery Talbert, Stephen G Henry, and Dikea Roussos-Ross.
• University of Florida, College of Pharmacy, Department of Pharmaceutical Outcomes and Policy, Gainesville, FL, USA; Center for Drug Evaluation & Safety, University of Florida, Gainesville, FL, USA.
• Res Social Adm Pharm. 2020 Sep 1; 16 (9): 1306-1308.

BackgroundPrescription drug monitoring programs (PDMPs) are primary prevention tools to reduce substance use disorders (SUD) and sequelae. Evidence regarding perceptions of PDMPs from different primary care providers, which may impact PDMP utilization for women, is unavailable.ObjectiveTo examine perceived PDMP effectiveness among obstetrician-gynecologists (OB/GYNs) compared to primary care physicians (PCPs).MethodsIndependent surveys of PDMP users in Florida, Kentucky, and California were evaluated based on a Likert-type item to assess perception of PDMP effectiveness in reducing prescription drug abuse and diversion. Response distributions of OB/GYNs versus PCPs were compared using chi-square tests.ResultsIn Florida, there were 41 OB/GYN and 511 PCP respondents; Kentucky, 46 OB/GYNs and 265 PCPs; and California, 41 OB/GYNs and 162 PCPs. In each state OB/GYNs viewed PDMPs as less effective, positive, or useful compared to PCPs (p ≤ 0.01, all states): Florida: 64.1% OB/GYN vs. 83.7% PCP "agree positive impact"; Kentucky: 45.0% OB/GYN vs. 68.5% PCP "effective". California: 73.2% OB/GYN vs. 86.4% PCP "useful".ConclusionsThese results suggest OB/GYNs view their state's PDMP as less effective than do PCPs, which may present barriers to PDMP utilization and decrease opportunities for SUD interventions. Engagement of all healthcare team members is needed to inform future strategies and policies to increase PDMP effectiveness.Copyright © 2019 Elsevier Inc. All rights reserved.

11 keywords...

hide…